nafamostat has been researched along with Splenic Diseases in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Splenic Diseases: Diseases involving the SPLEEN.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Murayama, Y | 1 |
| Nakanishi, T | 1 |
| Sakamura, Y | 2 |
| Okuno, M | 1 |
| Kiyohara, T | 1 |
| Yasunaga, Y | 1 |
| Kondo, S | 1 |
| Simizu, Y | 1 |
| Tarui, S | 1 |
1 other study available for nafamostat and Splenic Diseases
| Article | Year |
|---|---|
[Disappearance of pancreatic pseudocyst involving spleen with conservative therapy. Report of a case].
Topics: Adult; Benzamidines; Ceftizoxime; Cholangiopancreatography, Endoscopic Retrograde; Guanidines; Human | 1992 |